Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 13.34
INSM's Cash to Debt is ranked lower than
56% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. INSM: 13.34 )
Ranked among companies with meaningful Cash to Debt only.
INSM' s 10-Year Cash to Debt Range
Min: 0.86  Med: 260.64 Max: No Debt
Current: 13.34
F-Score: 3
Z-Score: 19.11
M-Score: -3.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -47.51
INSM's ROE (%) is ranked lower than
61% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. INSM: -47.51 )
Ranked among companies with meaningful ROE (%) only.
INSM' s 10-Year ROE (%) Range
Min: -460.81  Med: -48.04 Max: 195.47
Current: -47.51
-460.81
195.47
ROA (%) -39.65
INSM's ROA (%) is ranked lower than
62% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. INSM: -39.65 )
Ranked among companies with meaningful ROA (%) only.
INSM' s 10-Year ROA (%) Range
Min: -228.14  Med: -42.64 Max: 180.06
Current: -39.65
-228.14
180.06
ROC (Joel Greenblatt) (%) -1503.98
INSM's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. INSM: -1503.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INSM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -720550  Med: -7641.82 Max: -1133.76
Current: -1503.98
-720550
-1133.76
Revenue Growth (3Y)(%) -100.00
INSM's Revenue Growth (3Y)(%) is ranked lower than
92% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. INSM: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INSM' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -14.10 Max: 217.5
Current: -100
0
217.5
EBITDA Growth (3Y)(%) -7.70
INSM's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. INSM: -7.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INSM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -59.4  Med: -24.20 Max: 48.8
Current: -7.7
-59.4
48.8
EPS Growth (3Y)(%) -14.60
INSM's EPS Growth (3Y)(%) is ranked lower than
60% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. INSM: -14.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INSM' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.5  Med: -15.00 Max: 48.4
Current: -14.6
-59.5
48.4
» INSM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

INSM Guru Trades in Q3 2014

Steven Cohen 2,569,636 sh (+294.31%)
Steven Cohen 2,109,014 sh (unchged)
Steven Cohen 2,109,014 sh (unchged)
Steven Cohen 2,109,014 sh (unchged)
Jim Simons Sold Out
» More
Q4 2014

INSM Guru Trades in Q4 2014

Steven Cohen 2,840,830 sh (+10.55%)
» More
Q1 2015

INSM Guru Trades in Q1 2015

Paul Tudor Jones 27,175 sh (New)
Leon Cooperman 75,000 sh (New)
Steven Cohen Sold Out
» More
Q2 2015

INSM Guru Trades in Q2 2015

Paul Tudor Jones Sold Out
Leon Cooperman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INSM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.23
INSM's P/B is ranked higher than
50% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. INSM: 4.23 )
Ranked among companies with meaningful P/B only.
INSM' s 10-Year P/B Range
Min: 0.45  Med: 3.78 Max: 105
Current: 4.23
0.45
105
Current Ratio 7.94
INSM's Current Ratio is ranked higher than
67% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. INSM: 7.94 )
Ranked among companies with meaningful Current Ratio only.
INSM' s 10-Year Current Ratio Range
Min: 0.53  Med: 7.32 Max: 54.49
Current: 7.94
0.53
54.49
Quick Ratio 7.94
INSM's Quick Ratio is ranked higher than
69% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. INSM: 7.94 )
Ranked among companies with meaningful Quick Ratio only.
INSM' s 10-Year Quick Ratio Range
Min: 0.53  Med: 7.32 Max: 54.49
Current: 7.94
0.53
54.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.31
INSM's Price/Net Cash is ranked higher than
62% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. INSM: 5.31 )
Ranked among companies with meaningful Price/Net Cash only.
INSM' s 10-Year Price/Net Cash Range
Min: 0.57  Med: 4.40 Max: 197.5
Current: 5.31
0.57
197.5
Price/Net Current Asset Value 5.19
INSM's Price/Net Current Asset Value is ranked higher than
59% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. INSM: 5.19 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INSM' s 10-Year Price/Net Current Asset Value Range
Min: 0.52  Med: 4.36 Max: 156.67
Current: 5.19
0.52
156.67
Price/Tangible Book 5.06
INSM's Price/Tangible Book is ranked higher than
53% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. INSM: 5.06 )
Ranked among companies with meaningful Price/Tangible Book only.
INSM' s 10-Year Price/Tangible Book Range
Min: 0.51  Med: 4.20 Max: 90
Current: 5.06
0.51
90
Earnings Yield (Greenblatt) (%) -8.17
INSM's Earnings Yield (Greenblatt) (%) is ranked lower than
56% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. INSM: -8.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INSM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -9.34  Med: 35.40 Max: 8341.5
Current: -8.17
-9.34
8341.5

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 12 89
EPS($) -1.94 -1.98 -1.14
EPS without NRI($) -1.94 -1.98 -1.14

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IM8N.Germany,
Insmed Inc was incorporated in the Commonwealth of Virginia on November 29, 1999. The Company is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Its lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation, is a once-a-day inhaled antibiotic treatment engineered to deliver an anti-infective directly to the site of serious lung infections. It is currently conducting a phase 2 clinical trial in the United States and Canada of ARIKAYCE in patients who have lung infections caused by non-tuberculous mycobacteria. In 2013, it concluded a phase 3 clinical trial in Europe and Canada of ARIKAYCE in cystic fibrosis patients who have lung infections caused by Pseudomonas aeruginosa. The Company intends to develop ARIKAYCE to broaden the non-tuberculous mycobacteria indication and for additional indications beyond Pseudomonas in cystic fibrosis and non-tuberculous mycobacteria. ARIKAYCE received orphan drug status in the US and Europe for the treatment of non-tuberculous mycobacteria. The Company's registered trademarks are Insmed, ARIKACE, ARIKAYCE, and IPLEX. Its second proprietary compound is IPLEX, which is IGF-1, with its natural binding protein, IGFBP-3. IPLEX is no longer a development priority for the Company. Its competitors include pharmaceutical and biotechnology companies that have approved therapies or therapies in development for the treatment of chronic lung infections.
» More Articles for INSM

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CEO Buys Highlight: TPGI, INSM, EQU, FCEL Jan 13 2013 
INSMED Inc -- A Merger Ruined its Net-Net Status Feb 02 2011 
Insmed Inc. Reports Operating Results (10-Q) Nov 03 2010 
Insmed Inc. Reports Operating Results (10-Q) Aug 04 2010 
Insmed Inc. Reports Operating Results (10-Q) May 06 2010 
Jim Simons Low P/E Stocks: Insmed Inc., Paragon Shipping Inc., The Student Loan Corp., Hellenic Tele Apr 28 2010 
frankvis note on INSM Feb 08 2010 
8 Cheap Stocks Below Net Net Working Capital Dec 14 2009 
Insmed Inc. Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
INSMED INC Financials Aug 14 2015
10-Q for Insmed, Inc. Aug 09 2015
Edited Transcript of INSM earnings conference call or presentation 6-Aug-15 12:30pm GMT Aug 06 2015
Insmed reports 2Q loss Aug 06 2015
Insmed reports 2Q loss Aug 06 2015
INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2015
Insmed Reports Second Quarter 2015 Financial Results and Provides Business Update Aug 06 2015
INSMED INC Files SEC form 10-Q, Quarterly Report Aug 06 2015
Insmed to Host Second Quarter 2015 Financial Results Conference Call on Thursday, August 6, 2015 Jul 28 2015
Insmed to Participate at the JMP Securities Life Sciences Conference Jun 17 2015
Coverage initiated on Insmed by Citigroup Jun 09 2015
INSMED INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... May 21 2015
Insmed Announces Upcoming Data Presentations at the American Thoracic Society 2015 International... May 13 2015
Insmed to Participate at the UBS Global Healthcare Conference May 11 2015
Insmed reports 1Q loss May 07 2015
Insmed reports 1Q loss May 07 2015
INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 07 2015
INSMED INC Files SEC form 10-Q, Quarterly Report May 07 2015
Insmed Reports First Quarter 2015 Financial Results May 07 2015
INSMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK